ATTN: As of June 9, our Harbour View office in Suffolk has relocated to 3910 Bridge Road, Ste. 400.  

2025 UPDATES: Please bring all new insurance cards to your next appointment and verify your address and phone number when you check in at the front desk. 

Clinical Research & Trials

USO 23164

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (CB10A)

 

Disease Types: CAR-T

Eligibility Requirements:

• Histologically confirmed aggressive B-cell NHL
• DLBCL NOS, HGBL, transformed DLBCL from FL or
MZL, and PMBCL
• Documented CD19+ disease
• CD19 exposed patients only; documentation not
required for CD19 naïve patients
• ECOG status 0 or 1
• Prior systemic therapy (1 prior line) should include:
• An anti-CD20 antibody and an anthracycline.
• Relapsed or refractory disease
• Anti-CD19 targeting agent (CD19 relapsed cohort only)
• Donor HLA matching of ≥ 4 alleles with absence of DSA
• Subjects with active acute or chronic GvHD requiring therapy
are excluded
• Subjects with prior allogenic stem cell transplant are excluded

For more information on this trial CLICK HERE .

Available at: